High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer.

MicroRNA (Shariqah, United Arab Emirates) Pub Date : 2021-01-01 DOI:10.2174/2211536610666210412155206

Yanisa Rattanapan, Veerawat Korkiatsakul, Adcharee Kongruang, Teerapong Siriboonpiputtana, Budsaba Rerkamnuaychoke, Takol Chareonsirisuthigul

{"title":"High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer.","authors":"Yanisa Rattanapan, Veerawat Korkiatsakul, Adcharee Kongruang, Teerapong Siriboonpiputtana, Budsaba Rerkamnuaychoke, Takol Chareonsirisuthigul","doi":"10.2174/2211536610666210412155206","DOIUrl":null,"url":null,"abstract":"Background: Ovarian cancer is the most deadly cancer that requires novel diagnostics and therapeutics. MicroRNAs are viewed as essential gene regulatory elements involved in different pathobiological mechanisms of many cancers, including ovarian cancer.Objective: This study examined the relationship between microRNA (miRNA) expression and response to platinum-based chemotherapy.Methods: Genome-wide miRNA expression analysis was conducted using Epithelial Ovarian Cancer (EOC) tissues from 25 patients with 17 malignant tumors and eight benign ovarian tumors. Candidate miRNAs that respond to platinum-based chemotherapy were selected for validation by quantitative RT-PCR.Results: Among 2,578 mature human miRNAs, high expression of miR-483-5p correlated with poor responses to platinum-based chemotherapy in EOC patients. Furthermore, high levels of miR-483-5p in the resistant group suppressed expression of the apoptotic regulator TAOK-1.Conclusion: A possible marker for the prediction of chemotherapy response and resistance in patients may be miR-483-5p. Choosing the right treatment for each patient with EOC can avoid the risk of developing chemotherapy resistance.","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MicroRNA (Shariqah, United Arab Emirates)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2211536610666210412155206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Ovarian cancer is the most deadly cancer that requires novel diagnostics and therapeutics. MicroRNAs are viewed as essential gene regulatory elements involved in different pathobiological mechanisms of many cancers, including ovarian cancer.

Objective: This study examined the relationship between microRNA (miRNA) expression and response to platinum-based chemotherapy.

Methods: Genome-wide miRNA expression analysis was conducted using Epithelial Ovarian Cancer (EOC) tissues from 25 patients with 17 malignant tumors and eight benign ovarian tumors. Candidate miRNAs that respond to platinum-based chemotherapy were selected for validation by quantitative RT-PCR.

Results: Among 2,578 mature human miRNAs, high expression of miR-483-5p correlated with poor responses to platinum-based chemotherapy in EOC patients. Furthermore, high levels of miR-483-5p in the resistant group suppressed expression of the apoptotic regulator TAOK-1.

Conclusion: A possible marker for the prediction of chemotherapy response and resistance in patients may be miR-483-5p. Choosing the right treatment for each patient with EOC can avoid the risk of developing chemotherapy resistance.

查看原文本刊更多论文

miR-483-5p高表达预测上皮性卵巢癌化疗耐药

背景:卵巢癌是最致命的癌症，需要新的诊断和治疗方法。MicroRNAs被认为是参与许多癌症(包括卵巢癌)不同病理生物学机制的重要基因调控元件。目的:探讨microRNA (miRNA)表达与铂基化疗反应的关系。方法:对17例卵巢恶性肿瘤和8例卵巢良性肿瘤25例上皮性卵巢癌(EOC)组织进行全基因组miRNA表达分析。选择对铂类化疗有反应的候选mirna进行定量RT-PCR验证。结果:在2578个成熟的人类mirna中，miR-483-5p的高表达与EOC患者对铂类化疗的不良反应相关。此外，耐药组中高水平的miR-483-5p抑制了凋亡调节因子taok1的表达。结论:miR-483-5p可能是预测患者化疗反应和耐药的标志物。为每个EOC患者选择正确的治疗方法可以避免产生化疗耐药的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MicroRNA (Shariqah, United Arab Emirates) Medicine-Medicine (all)

自引率

0.00%

发文量